It is an exciting time in cancer drug discovery. Seven in 10 people now survive their cancer five years or more, up from only half in the mid-70s, according to the American Cancer Society’s 2026 Cancer Statistics.

New modalities, like radiopharmaceuticals, alongside new drug targets, like KRAS mutations, are resulting in therapies that can be more targeted and more personalised than ever before.

This DDW Guide explores the latest advancements in cancer research, including an overview of recent market developments, how to selectively degrade essential proteins, the potential of KRAS inhibitors and novel approaches to radiotherapy.

Download your copy now.